How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Market Analysis

Background:

• Drug copayment coupons reduce out-of-pocket expenses for patients.
• These coupons are prevalent for branded drugs but banned in Medicare Advantage.
• Understanding their market impact is crucial for policy evaluation.

Purpose of the Study:

• To estimate the causal impact of drug copayment coupons on drug pricing and sales.
• To analyze the differential effects between commercial insurance and Medicare Advantage.
• To quantify the equilibrium price effects of coupon availability.

Main Methods:

• Analysis of drug sales data, comparing segments with and without coupon bans.
• Estimation of a discrete choice demand model for multiple sclerosis drugs.
• Simulation of a drug price negotiation model to assess equilibrium outcomes.

Main Results:

• Coupon introduction increased quantity sold by 23-25% in the commercial segment compared to Medicare Advantage.
• Net-of-rebate prices for branded drugs without generic substitutes were estimated to be 8% higher due to coupon availability.
• Significant impact on both demand and net prices observed.

Conclusions:

• Drug copayment coupons substantially boost sales of branded drugs.
• The availability of coupons leads to higher net-of-rebate prices, impacting market dynamics.
• Policy implications for drug pricing and accessibility need consideration.